Progress in the treatment of diabetes type 1 and 2

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 13, Issue 1, 2007, Pages 47-51

  Wa̧sikowa, Renata B ^a,b   Basiak, Aleksander ^a  

^a Katedra i Klinika Endokrynologii   (Poland)

^b NONE   (Poland)

Author keywords

Diabetes type 1; Diabetes type 2; Diabetes type 2 in children; Progress in the therapy; Transplantation

Indexed keywords

AMYLIN; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIAMYD; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUTAMATE DECARBOXYLASE 65; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLUSILIN; INSULIN LISPRO; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; RECOMBINANT GLUTAMATE DECARBOXYLASE 65; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TIAZOLIDINEDIODE DERIVATIVE; UNCLASSIFIED DRUG;

CELL TRANSPLANTATION; CLINICAL TRIAL; CONTINUOUS INFUSION; COUGHING; DIABETES CONTROL; DISEASE COURSE; DRUG ABSORPTION; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; METABOLIC REGULATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; REVIEW;

EID: 84904848227     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Kim K.W.: Islet transplantation: a realistic alternative for the treatment of insulin deficient diabetes mellitus. Diabetes Res. Clin. Pract., 2004, 66, 11-17.
2. Quattrin T.: Inhaled insulin: recent advances in the therapy of type 1 and 2 diabetes. Expert Opin. Pharmacother., 2004, 5, 2597-2604.
3. Rosenstock J., Foyt H., Klioze S. et al.: Inhaled human insulin (Exubera) therapy shows sustained efficacy over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes, 2006, suppl. 1, 109.
4. Muchmore D.B.: Inhaled insulin delivery - where are we now? Diabetes, 2006, 55, 1
5. Ergun-Longmire B., Marker J., Zeidler A. et al.: Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Am. N.Y. Acad. Sci., 2004, 1029, 260-277.
6. Skyler J., Jovanovic L., Klioze S. et al.: Sustained efficacy and tolerability of inhaled human insulin (Exubera). Therapy over 2 years: patients with type 1 diabetes. Diabetologia, 2006, 49, 186.
7. Finucane K.A., Archer C.B.: Recent advances in diabetology: diabetic dermopathy autoantibodies in the prediction of the development of type 1 diabetes and islet cell transplantation and inhaled insulin as treatment for diabetes. Clin. Exp. Dermatol, 2006, 31, 837-840.
8. Ludvigson J., Csas R., Vaarala O. et al.: The Swedish GAD-vaccination Trial: outcomes of a phase II safety and efficacy trial with Diamyd TM for preservation of beta cell function in children with T1D. Diabetologia, 2006, 49, suppl. 1, 149, 236.
9. Pettis R.J., Hompesch M., Kapitra C. et al.: Intradermal insulin Lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection. Diabetes, 2006, 55, suppl. 1, 108.
10. Burdick P., Cooper S., Horner B. et al.: Use of insulin Injection Port to improve glycemic control in children with type 1 diabetes. Diabetes, 2006, 55, suppl. 1, A55, 236.
11. Rigla M., Hernando M., Gomes E.J. et al.: Glycaemic control improvement with the weekly use of "guardian rt together with a wireless assistant for asynchronic remote advice in pump treated type 1 diabetic patients. Diabetologia, 2006, 49, suppl. 1, 153, 243.
12. Lutseiko M., Clark B., Voskanyan G., Steil G.M.: Automated closed loop insulin delivery utilizing insulin feedback. Diabetes, 2006, 55, suppl. 1, A27, 113.
13. Schlotthauer G.: Modeling, identification and nonlinear model predictive control of type 1 diabetic patient. Med. Eng. Phys., 2006, 28, 240-250.
14. Steiner S.: Technosphere insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp. Clin. Endocrinol. Diabetes, 2002, 110, 17-21.
15. Boss A.H., Evans S.H., Ren H. et al.: Superior postprandial glucose control in patients with type 1 diabetes when using prandial technosphere insulin compared to Novo-Log. Diabetologia, 2006, 49, 114-115.
16. Edelman S.: Amylin replacement therapy in patients with type 1 diabetes. Diab. Educ., 2006, 32, 1145-1275.
17. Edelman S., Garg S., Frias J. et al.: A double blind, placebo-controlled trial assessing pramlintiale treatment in the setting of intensive insulin. Koeterman Diabetes Care, 2006, 29, 2184-2195.
18. Secchi A., Socci C., Maffi P. et al.: Islet transplantation in IDDM patients. Diabetologia, 1997, 40, 225.
19. Ono Rinsko-Byari O.J.: Treatment of type 1 diabetes by transplantation of isolated pancreatic islets. Jap. J. Klin. Pathol., 2006, 54, 379-385.
20. Fernandez J., King A., Hollisterlock J. et al.: Transplants of the beta cells alone without accompanying islet non-beta cells successfully reverse diabetes. Diabetes, 2006, 55, suppl. 1, A 23, 96.
21. Thompson D.M., Fung M.A., Meneilly G.S. et al.: Exanatide improves glucose control in islet cell transplant recipients. Diabetes, 2006, A 55, suppl. 1, 95.
22. Huang Y., Yan J., Wang D. et al.: Bone narrow cells contribute to a cell regeneration. Diabetes, 2006, 55, A 23, 98.
23. Sisino G., Dogra R., Allende G. et al.: Evidence for ductall cell to beta-cell trans-differentiation and proliferation in the transplanted pancreas of patients with type 1 diabetes and recurrence of autoimmunity. Diabetes, 2006, 55, 136.
24. Shapiro A.M.J. et al.: International trial of the Edmonton Protocoll for islet transplantation. N.E.J.M., 2006, 355, 1318-1330.
25. Longoni B., Paoli G., Szilagyi E. et al.: Mesenchymal stem cells modulate allogenic response in pancreatic islet. Diabetologia, 2006, 49, suppl. 1, 271-272.
26. Reinehr T.: Clinical presentation of type 2 diabetes mellitus in children and adolescents. Intern. Your Obesity, 2005, 105-110.
27. Gunger N., Janosky J., Thompson T. et al.: Early signs of cardiovascular disease in youth with ubesity and type 2 diabetes. Diabetes Care, 2005, 28, 1219-1221.
28. Eppens M.C., Craig M.E., Cusumano J. et al.: Prevalence of diabetic complications in adolescents with type 2 compared with type 1 diabetes. Diab. Care, 2006, 29, 1300-1306.
29. Strowski M.Z.: Novel antibodies therapeutics - oral information. 2006, 18, 11.
30. Burkey B.F., Russel M., Wang K. et al.: Vildagliptin displays sow tight-binding to dipeptidyl peptidase (DPP-4) but not DPP-8 or DPP-9. Diabetologia, 49, 477-478.
31. Nauck M.A., Duran S., Kim D. et al.: Efects of exenatide compared with twice-daily biphasic insulin as part in patients with type 2 diabetes using metformin and a sulphanyl. Diabetologia Urea, 2006, 49, 1.
32. Maggs D.D., Marc-Conell L., Zhuang D. et al.: Safety and effects of a once-weekly long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes. Diabetologia, 2006, 49, 2.
33. Caurreges J.P., Zdrawkovic M., Le-Thi T. et al.: Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes; 14 weeks monotherapy study. Diabetologia, 2006, 49, 3.
34. Aschner P., Kipnes M., Lanceford J. et al.: Sitagliptin monotherapy improves glycaemic control in patients with type 2 diabetes. Diabetologia, 2006, 49, 5.
35. Meininger G., Charbonnel B., Karasik A. et al.: Efficacy and safety of sitagliptin added to ongoing metformin therapy in type 2 diabetes patients who were inadequately controlled on metformin alone. Diabetologia, 2006, 49, 6.
36. Nanaka K., Kalikowa T., Sato A. et al.: Twelve-week efficacy and tolerabilty of sitagliptin, a Dipeptidyl peptidase (DPP4) inhibitor In Japanese patients with type 2 diabetes. Diabetologia, 2006, 49, 25-36.
37. Bodalski J. Szadkowska A., Mtynarski W.: Ogólnopolski rejestr cukrzycy typu 1 - nadzieje i oczekiwania. Przegl. Pediatr., 2006, 36, 175-178.